| Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Controlled Trial | |
| Alternative Title | Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Controlled Trial |
| Cai XiaoLing1; Chen YingLi1; Zhao JiaJun2; Shan ZhongYan3; Qiu MingCai4; Li ChengJiang5; Gu Wei5; Tian HaoMing6; Yang HuaZhang7; Xue YaoMing7; Yang JinKui8; Hong TianPei1; Ji LiNong1 | |
| 2015 | |
| Source Publication | Chinese Medical Journal
 |
| ISSN | 0366-6999 |
| Volume | 128Issue:10Pages:1279-1287 |
| Abstract | Background: At present, China has listed the compound tablet containing a fixed dose of rosiglitazone and metformin, Avandamet, which may improve patient compliance. The aim of this study was to evaluate the efficacy and safety of Avandamet or uptitrated metformin treatment in patients with type 2 diabetes inadequately controlled with metformin alone. Methods: This study was a 48-week, multicenter, randomized, open-labeled, active-controlled trial. Patients with inadequate glycaemic control (glycated hemoglobin HbA1c 7.5-9.5%) receiving a stable dose of metformin (≥1500 mg) were recruited from 21 centers in China (from 19 November, 2009 to 15 March, 2011). The primary objective was to compare the proportion of patients who reached the target of HbA1c ≤7% between Avandamet and metformin treatment. Results: At week 48, 83.33% of patients reached the target of HbA1c ≤7% in Avandamet treatment and 70.00% in uptitrated metformin treatment, with significantly difference between groups. The target of HbA1c ≤6.5% was reached in 66.03% of patients in Avandamet treatment and 46.88% in uptitrated metformin treatment. The target of fasting plasma glucose (FPG) ≤6.1 mmol/L was reached in 26.97% of patients in Avandamet treatment and 19.33% in uptitrated metformin treatment. The target of FPG ≤7.0 mmol/L was reached in 63.16% of patients in Avandamet treatment and 43.33% in uptitrated metformin treatment. Fasting insulin decreased 3.24 ± 0.98 μU/ml from baseline in Avandamet treatment and 0.72 ± 1.10 μU/ml in uptitrated metformin treatment. Overall adverse event (AE) rates and serious AE rates were similar between groups. Hypoglycaemia occurred rarely in both groups. Conclusions: Compared with uptitrated metformin, Avandamet treatment provided significant improvements in key parameters of glycemic control and was generally well tolerated. Registration number: ChiCTR-TRC-13003776. |
| Other Abstract | Background: At present, China has listed the compound tablet containing a fixed dose of rosiglitazone and metformin, Avandamet, which may improve patient compliance. The aim of this study was to evaluate the efficacy and safety of Avandamet or uptitrated metformin treatment in patients with type 2 diabetes inadequately controlled with metformin alone. Methods: This study was a 48-week, multicenter, randomized, open-labeled, active-controlled trial. Patients with inadequate glycaemic control (glycated hemoglobin HbA1c 7.5–9.5%) receiving a stable dose of metformin (≥1500 mg) were recruited from 21 centers in China (from 19 November, 2009 to 15 March, 2011). The primary objective was to compare the proportion of patients who reached the target of HbA1c ≤7% between Avandamet and metformin treatment. Results: At week 48, 83.33% of patients reached the target of HbA1c ≤7% in Avandamet treatment and 70.00% in uptitrated metformin treatment, with significantly difference between groups. The target of HbA1c ≤6.5% was reached in 66.03% of patients in Avandamet treatment and 46.88% in uptitrated metformin treatment. The target of fasting plasma glucose (FPG) ≤6.1 mmol Conclusions: Compared with uptitrated metformin, Avandamet treatment provided significant improvements in key parameters of glycemic control and was generally well tolerated. Registration number: ChiCTR-TRC-13003776. |
| Keyword | Avandamet Medicine R Efficacy Type 2 Diabetes |
| Indexed By | CSCD |
| Language | 英语 |
| Funding Project | [GlaxoSmithKline] |
| CSCD ID | CSCD:5419638 |
| Citation statistics |
Cited Times:2[CSCD]
[CSCD Record]
|
| Document Type | 期刊论文 |
| Identifier | http://ir.imr.ac.cn/handle/321006/153604 |
| Collection | 中国科学院金属研究所 |
| Affiliation | 1.北京大学 2.Shandong Prov Hosp, Department Endocrinol & Metab, Jinan 250021, Shandong, Peoples R China 3.中国科学院金属研究所 4.Tianjin Med University, Gen Hosp, Dept Endocrinol & Metab, Tianjin 300070, Peoples R China 5.浙江大学 6.四川大学 7.中国科学院广州地球化学研究所 8.Beijing Tongren Hosp, Department Endocrinol & Metab, Beijing 100730, Peoples R China |
| Recommended Citation GB/T 7714 | Cai XiaoLing,Chen YingLi,Zhao JiaJun,et al. Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Controlled Trial[J]. Chinese Medical Journal,2015,128(10):1279-1287. |
| APA | Cai XiaoLing.,Chen YingLi.,Zhao JiaJun.,Shan ZhongYan.,Qiu MingCai.,...&Ji LiNong.(2015).Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Controlled Trial.Chinese Medical Journal,128(10),1279-1287. |
| MLA | Cai XiaoLing,et al."Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Controlled Trial".Chinese Medical Journal 128.10(2015):1279-1287. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment